OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 48 weeks (wks) in the RAPID-PsA trial. METHODS: The ongoing RAPID-PsA trial (NCT01087788) is double-blind and placebo-controlled to Wk24 and dose-blind to Wk48. Patients (pts) had active PsA and had failed ≥1 DMARD. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind phase; placebo pts entering dose-blind phase were re-randomized to CZP loading dose followed by CZP 200mg Q2W or 400mg Q4W. We report efficacy data for the randomised set (RS) of pts originally randomized to CZP. Mean changes from baseline in patient assessment of pain (VAS), fatigue assessment scale (NRS), HAQ-DI, SF-36, PsAQoL and Dermatology Life Quality Index (DLQI) were assessed with LOCF imputation. RESULTS: Of 138 and 135 pts randomized to CZP 200mg Q2W and 400mg Q4W, 128 (92.8%) and 120 (88.9%) completed the double-blind period, and 123 (89.1%) and 114 (84.4%) completed the dose-blind period, respectively. Rapid improvements from baseline to Wk24 observed in double-blind period were maintained to Wk48 for pain (Wk24: -28.6 and -28.4; Wk48: -31.6 and -29.5), fatigue (Wk24: -2.2 and -1.9; Wk48: -2.4 and -2.0), HAQ-DI (Wk24: -0.52 and -0.43; Wk48: -0.56 and -0.49), SF-36 physical component summary (Wk24: 8.4 and 7.6; Wk48: 8.6 and 8.4) and mental component summary (Wk24: 5.5 and 3.5; Wk48: 4.8 and 3.2), PsAQoL (Wk24: -4.4 and -3.3; Wk48: -4.8 and -3.5), and DLQI (Wk24: -6.3 and -5.2; Wk48: -6.2 and -5.6) for CZP 200mg Q2W and 400mg Q4W patients, respectively.  CONCLUSIONS: Improvements in generic and disease-specific PROs observed over 24 wks were sustained over 48 wks in CZP-treated PsA pts. Improvements were observed regardless of CZP dose regimen.